News

As part of the deal, Waterstone has an option to license two additional cyclophilin inhibitors from Scynexis. In return, Scynexis will receive an upfront payment and is eligible

An active moiety of the prodrug isavuconazonium, Isavuconazole is an investigational once-daily intravenous and oral broad-spectrum antifungal being developed to treat severe invasive and life-threatening fungal infections. The

The drug is indicated for the long-term, once-daily, add-on maintenance treatment of asthma in patients 12 years of age and older who remain symptomatic on at least inhaled

Under the new $4.8m strategic alliance, ex scientia received an upfront payment of $1m. As part of the deal, Sunovion will receive exclusive worldwide rights to the resulting

These data demonstrate that Fluzone High-Dose vaccine provided improved protection against influenza ("the flu") compared to standard-dose Fluzone vaccine (trivalent intramuscular formulation) in adults 65 years of age

The effectiveness of aripiprazole once-monthly (aripiprazole extended-release injectable suspension, for intramuscular use: Abilify Maintena) and paliperidone palmitate (paliperidone palmitate extended-release injectable suspension, for intramuscular use) in adult patients

Under the terms of the agreement, Intra-Cellular Therapies has regained all worldwide development and commercialization rights for the compounds previously licensed to Takeda. Takeda will be responsible for

The clinical-stage biotechnology company has obtained exclusive worldwide rights to use human insulin producing cells, termed "Melligen" cells, developed by University of Technology – Sydney’s (UTS) Professor Ann

Now through November 22, CVS/pharmacy customers will have the opportunity to support Stand Up To Cancer (SU2C) at the register in stores nationwide and online at www.cvs.com/SU2C. SU2C